We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novartis' Rhapsido Gets Positive CHMP Opinion for Urticaria in EU
Read MoreHide Full Article
Key Takeaways
NVS received CHMP support for remibrutinib to treat CSU patients unresponsive to H1 antihistamines.
Phase III REMIX studies showed improved itch, hives and quality of life through week 52.
Rhapsido is FDA-approved and is also being studied for other immune-mediated diseases.
Novartis (NVS - Free Report) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending marketing authorization for remibrutinib as an oral treatment for adult patients with chronic spontaneous urticaria (CSU) who have an inadequate response to histamine-1 antihistamines (H1AH). The final decision of the European Commission is expected in the coming two months.
Remibrutinib was approved in the United States under the brand name “Rhapsido” for the said patient population in September 2025, marking it the first FDA-approved oral Bruton’s tyrosine kinase inhibitor (BTKi) for CSU. The therapy is also approved in China.
CHMP Nod to NVS’ Rhapsido Based on Phase III Studies
The positive opinion by CHMP is supported by data from late-stage REMIX-1 and REMIX-2 studies on patients who remained symptomatic on second-generation H1AH. The studies demonstrated significant improvements in itch and hives, with sustained benefits through week 52 from baseline. Rhapsido also improved quality of life, while demonstrating a favorable safety profile with no liver safety concerns.
More on NVS’ Rhapsido
Rhapsido is a highly selective oral BTK inhibitor designed to reduce histamine release, thereby alleviating CSU symptoms.
Beyond CSU, Novartis is advancing Rhapsido for additional indications. The company announced positive data from the phase III RemIND study evaluating Rhapsido in chronic inducible urticaria. The drug is also being evaluated for other immune-mediated conditions like hidradenitis suppurativa and food allergies, further broadening Novartis’ immunology pipeline.
CSU is a chronic skin disease characterized by recurrent itchy hives and/or angioedema without an external trigger, affecting about 40 million people worldwide. The disease imposes a substantial burden on patients, often disrupting sleep, contributing to anxiety and depression, and impairing workplace productivity.
Regeneron Pharmaceuticals (REGN - Free Report) and its partner Sanofi (SNY - Free Report) announced yesterday that the CHMP of the EMA has also issued a positive opinion recommending the expanded use of their blockbuster drug, Dupixent, for treating moderate-to-severe CSU in children. The recommendation supports Dupixent’s use in CSU patients aged 2 to 11 years who have an inadequate response to histamine-1 antihistamines and who are naive to anti-immunoglobulin E therapy. A final decision of the European Commission is expected in the coming months.
Regeneron has a global strategic collaboration with Sanofi for the discovery, development and commercialization of Dupixent. Under the collaboration agreement, Sanofi records global net product sales of Dupixent and Kevzara while Regeneron records its share of profits or losses in connection with the global sales of the drugs.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Novartis' Rhapsido Gets Positive CHMP Opinion for Urticaria in EU
Key Takeaways
Novartis (NVS - Free Report) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending marketing authorization for remibrutinib as an oral treatment for adult patients with chronic spontaneous urticaria (CSU) who have an inadequate response to histamine-1 antihistamines (H1AH). The final decision of the European Commission is expected in the coming two months.
Remibrutinib was approved in the United States under the brand name “Rhapsido” for the said patient population in September 2025, marking it the first FDA-approved oral Bruton’s tyrosine kinase inhibitor (BTKi) for CSU. The therapy is also approved in China.
CHMP Nod to NVS’ Rhapsido Based on Phase III Studies
The positive opinion by CHMP is supported by data from late-stage REMIX-1 and REMIX-2 studies on patients who remained symptomatic on second-generation H1AH. The studies demonstrated significant improvements in itch and hives, with sustained benefits through week 52 from baseline. Rhapsido also improved quality of life, while demonstrating a favorable safety profile with no liver safety concerns.
More on NVS’ Rhapsido
Rhapsido is a highly selective oral BTK inhibitor designed to reduce histamine release, thereby alleviating CSU symptoms.
Beyond CSU, Novartis is advancing Rhapsido for additional indications. The company announced positive data from the phase III RemIND study evaluating Rhapsido in chronic inducible urticaria. The drug is also being evaluated for other immune-mediated conditions like hidradenitis suppurativa and food allergies, further broadening Novartis’ immunology pipeline.
CSU is a chronic skin disease characterized by recurrent itchy hives and/or angioedema without an external trigger, affecting about 40 million people worldwide. The disease imposes a substantial burden on patients, often disrupting sleep, contributing to anxiety and depression, and impairing workplace productivity.
Regeneron Pharmaceuticals (REGN - Free Report) and its partner Sanofi (SNY - Free Report) announced yesterday that the CHMP of the EMA has also issued a positive opinion recommending the expanded use of their blockbuster drug, Dupixent, for treating moderate-to-severe CSU in children. The recommendation supports Dupixent’s use in CSU patients aged 2 to 11 years who have an inadequate response to histamine-1 antihistamines and who are naive to anti-immunoglobulin E therapy. A final decision of the European Commission is expected in the coming months.
Regeneron has a global strategic collaboration with Sanofi for the discovery, development and commercialization of Dupixent. Under the collaboration agreement, Sanofi records global net product sales of Dupixent and Kevzara while Regeneron records its share of profits or losses in connection with the global sales of the drugs.